仟源医药：拟与关联方等共同向子公司仟源研发增资

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) is accelerating the research and development of precision narcotic drugs by increasing capital in its subsidiary, QianYuan Pharmaceutical Research and Development (Shanghai) Co., Ltd. This move aims to optimize product structure, enhance overall competitiveness, and motivate the R&D team while managing resources and reducing costs [1] Group 1: Capital Increase Details - The company, along with professional investors and institutions, is increasing capital in QianYuan R&D with a total of 8,000,000 CNY allocated to registered capital and an additional 800,000 CNY to capital reserves [1] - The capital contributions are as follows: QianYuan contributes 18.7 million CNY, Rongliang contributes 19.8 million CNY, Wutong Sanjiang II contributes 9.9 million CNY, Jiangsu Weijia contributes 29.7 million CNY, and QianYuan R&D contributes 9.9 million CNY [1] - After the capital increase, QianYuan holds a 30% stake, Rongliang holds 20%, Wutong Sanjiang II holds 10%, Jiangsu Weijia holds 30%, and QianYuan R&D holds 10% [1]